Talk:Allopurinol

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
High	This article has been rated as High-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Allopurinol.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Problems in text fixed

Fixed a few problems:

Revision 344565878 by 125.60.240.216 removed the word "not" from "Because allopurinol is not a uricosuric..." But that doesn't make sense; see uricosuric.
Revision 344565770 by the same IP address changed the word "severe" to "nothing" in "Allopurinol can cause severe pancytopenia..." That doesn't make sense, and it's not even a grammatical sentence.
The reference to the Dalbeth Stamp article was garbled - it had a chunk of repeated text from this article pasted into the middle of it.

StormWillLaugh (talk) 10:59, 4 March 2010 (UTC)[reply]

Formula

The formula is incorrect.

This is the correct formula :

http://www.uft.uni-bremen.de/chemie/SAR-Buch/jpg/allopurinol.gif —Preceding unsigned comment added by NennMichMeister (talk • contribs) 20:47, 12 September 2010 (UTC)[reply]

Corrections / Update

While on the whole this article is quite well written, there are number of factual errors, and it requires updating. I am doing this, as well as adding refs for new parts and missing citations. - JD 8 Sep 12 — Preceding unsigned comment added by Johnaduley (talk • contribs) 13:35, 8 September 2012 (UTC) Edit completed Johnaduley (talk) 14:36, 8 September 2012 (UTC)[reply]

Synthesis reported first by RK Robins in 1956

The text says Elion invented allopurinol as a cancer drug metabolism inhibitor. Wrong. Elion tried it for that, but took the drug off the shelf as an already known molecule. Elion does not claim otherwise in the cited Nobel lecture. Allopurinol was first synthesized and reported by Roland K. Robins (1926-1992) an old mentor of mine. The ref is R. K. Robins, J. Amer. Chem. Soc.,78, 784 (1956). S B H arris 15:27, 24 April 2013 (UTC)[reply]

Renal Disease section

What does this mean?

"Allopurinol can be used in patients with poor kidney function, but it may also help them."

It certainly is poor wording but I can't change it without knowing more. Maybe "can be used... and may even improve kidney function"? Arbalest Mike (talk) 23:24, 26 April 2014 (UTC)[reply]

Fatal Hypersensitivity Reactions

Stern RJ.
Editor's Note: Reducing Life-Threatening Allopurinol Hypersensitivity
http://archinte.jamanetwork.com/article.aspx?articleID=2397728
JAMA Intern Med. Published online July 20, 2015.
doi:10.1001/jamainternmed.2015.3546

Yang C, Chen C, Deng S, et al.
Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.
http://archinte.jamanetwork.com/article.aspx?articleID=2397733
JAMA Intern Med. Online July 20, 2015.
doi:10.1001/jamainternmed.2015.3536.

This study was in Taiwan, with a 95% Han Chinese population, with high incidence of HLA-B*5801 and 4 times the incidence of allopurinol hypersensitivity syndrome as the U.S. In Taiwan, the mortality among new users was 0.39/1,000 and the incidence of hypersensitivity was 4.68/1,000. Renal and cardiovascular disease are risk factors. --Nbauman (talk) 02:40, 24 July 2015 (UTC)[reply]

Better sourcing

Per the tag, this should be sourced better and restored:

Research

Allopurinol can be used in patients with poor kidney function. A study of allopurinol use in patients with chronic kidney disease suggested, "Allopurinol decreases C-reactive protein and slows the progression of renal disease in patients with chronic kidney disease. In addition, it reduces cardiovascular and hospitalization risk in these subjects."^[1]

A mechanistic study in patients with chronic heart failure has shown the actions of allopurinol may be due to its inhibition of xanthine oxidase rather than a urate-lowering effect. This study also showed, for the first time, a high dose (600 mg) is significantly better at improving endothelial function compared to standard doses.^[2]

A recent study has suggested allopurinol may help reduce the effects of angina in ischaemic heart disease by reducing the workload on the heart.^[3]

Allopurinol can decrease blood pressure, thus reducing hypertension.^[4]

References

^ Goicoechea, M.; De Vinuesa, S. G.; Verdalles, U.; Ruiz-Caro, C.; Ampuero, J.; Rincón, A.; Arroyo, D.; Luño, J. (2010). "Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk". Clinical Journal of the American Society of Nephrology. 5 (8): 1388–93. doi:10.2215/CJN.01580210. PMC 2924417. PMID 20538833..
^ George, J; Carr, E; Davies, J; Belch, JJ; Struthers, A (2006). "High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid". Circulation. 114 (23): 2508–16. doi:10.1161/CIRCULATIONAHA.106.651117. PMID 17130343.
^ "Gout drug 'can prevent angina pain of heart disease'". BBC News. 8 June 2010.
^ Feig, D. I.; Soletsky, B.; Johnson, R. J. (2008). "Effect of Allopurinol on Blood Pressure of Adolescents with Newly Diagnosed Essential Hypertension: A Randomized Trial". JAMA: the Journal of the American Medical Association. 300 (8): 924–32. doi:10.1001/jama.300.8.924. {{cite journal}}: Unknown parameter |laydate= ignored (help); Unknown parameter |laysource= ignored (help); Unknown parameter |laysummary= ignored (help)

-- Jytdog (talk) 06:42, 29 August 2016 (UTC)[reply]

Gout

How long should you take allapurinol 2600:1005:B053:CF2C:8D1A:960A:881F:2292 (talk) 00:14, 13 July 2022 (UTC)[reply]

It only reduces the levels of uric acid while you are taking it, so it would only be useful in preventing gout W;ChangingUsername (talk) 03:14, 18 October 2024 (UTC)[reply]

Oxypurinol in tumor lysis syndrome

Didn't oxypurinol (a metabolite of allo) replace this as a drug they gave for tumor/necrosis? I think it said on a "compassion-basis"

Oxypurinol also has interactions with TNF W;ChangingUsername (talk) 03:13, 18 October 2024 (UTC)[reply]

[1] Goicoechea, M.; De Vinuesa, S. G.; Verdalles, U.; Ruiz-Caro, C.; Ampuero, J.; Rincón, A.; Arroyo, D.; Luño, J. (2010). "Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk". Clinical Journal of the American Society of Nephrology. 5 (8): 1388–93. doi:10.2215/CJN.01580210. PMC 2924417. PMID 20538833..

[2] George, J; Carr, E; Davies, J; Belch, JJ; Struthers, A (2006). "High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid". Circulation. 114 (23): 2508–16. doi:10.1161/CIRCULATIONAHA.106.651117. PMID 17130343.

[3] "Gout drug 'can prevent angina pain of heart disease'". BBC News. 8 June 2010.

[Journal_Watch_Specialties-4] Feig, D. I.; Soletsky, B.; Johnson, R. J. (2008). "Effect of Allopurinol on Blood Pressure of Adolescents with Newly Diagnosed Essential Hypertension: A Randomized Trial". JAMA: the Journal of the American Medical Association. 300 (8): 924–32. doi:10.1001/jama.300.8.924. {{cite journal}}: Unknown parameter |laydate= ignored (help); Unknown parameter |laysource= ignored (help); Unknown parameter |laysummary= ignored (help)

[1]

[2]

[3]

[4]